Department of Pharmaceutical Chemistry

Research directed by senior author James Wells, PhD, chair of the Department of Pharmaceutical Chemistry, UCSF School of Pharmacy, has opened the door to a new way of studying and better understanding the processes of cell death (apoptosis), blood clotting, and other biochemic

A computational method developed in the UCSF School of Pharmacy under the direction of faculty member Brian Shoichet, PhD, has the potential to predict new target diseases for existing drugs as well as unexpected side effects of approved drugs.

The Scientist has cited a UCSF innovation among its top 10 list of tools to hit the life sciences in 2009. In the spotlight is a paper that reveals how to import plant "light switches" into mammalian cells to control complex regulatory processes. The paper appeared in the October 15, 2009 issue of...

Takeda San Francisco, Inc., announced September 21, 2009 that it has entered into a sponsored collaboration with UCSF to support antibody-related research in the laboratory of Charles S.

Scientists from the UCSF School of Pharmacy's Department of Pharmaceutical Chemistry have been selected to lead a new federal initiative aimed at developing new classes of drugs to target cancer.

UCSF School of Pharmacy researchers and colleagues have successfully created a mathematical model that genetically programs bacteria and causes the bacteria to "trace" images projected onto them in a petri dish. The bacteria sense and display the area of the projection where light meets dark by...

Mitra Assemi, PharmD, UCSF School of Pharmacy associate professor of clinical pharmacy, has been named the School's assistant dean of accreditation and quality, effective September 1, 2009.

Donald Kishi, PharmD, UCSF School of Pharmacy health sciences clinical professor of pharmacy, has been named the School's associate dean of student and curricular affairs by Dean Mary Anne Koda-Kimble, PharmD.

A team of scientists from UCSF and colleagues have identified a new potential drug target for the herpes virus that causes Kaposi’s sarcoma. Their research reopens the possibility of using a class of drugs called protease inhibitors, against diseases ranging from cancer to Alzheimer's Disease.